Literature DB >> 11694403

The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance.

H Gregersen1, L Mellemkjaer, J S Ibsen, J F Dahlerup, L Thomassen, H T Sørensen.   

Abstract

BACKGROUND AND OBJECTIVES: In this study the impact of gender, age, type of M-component and concentration of immunoglobulins on the risk of malignant transformation in monoclonal gammopathy of undetermined significance (MGUS) was assessed. DESIGN AND METHODS: We identified 1,247 cases of MGUS in the period 1978 to 1993 in North Jutland County, Denmark. Data on cancer occurrence in the MGUS cohort were obtained from the Danish Cancer Registry. The expected numbers of incident cancer cases were calculated from age-, sex-, county-, and period-specific cancer incidence rates. The impact of the variables mentioned above on the risk of malignant transformation was analyzed in Poisson regression models.
RESULTS: The relative risk of IgA compared to IgG was 1.8 (95% confidence interval, 1.1-3.0), while the relative risk of IgM compared to IgG was 1.1 (0.7-1.9). For all three types of MGUS, the risk of malignant transformation was higher among females than among males, and the risk increased with increasing concentration of immunoglobulin with very high risks for the patients with the highest levels of immunoglobulin. Hypogammaglobulinemia was associated with malignant transformation in patients with IgG type MGUS. For IgG and IgM MGUS, the risk decreased with increasing age and with follow-up beyond one year. INTERPRETATION AND
CONCLUSIONS: Female sex, IgA M-component type and high concentration of the immunoglobulin comprising the M-component were associated with a high risk of malignant transformation. Hypogammaglobulinemia, young age at diagnosis and short follow-up were risk factors in particular for those with IgG MGUS.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11694403

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  10 in total

1.  Incidental finding of monoclonal gammopathy in blood donors: a follow-up study.

Authors:  Massimo La Raja; Monica Barcobello; Nicola Bet; Paolo Dolfini; Marina Florean; Federica Tomasella; Vincenzo De Angelis; Luca Mascaretti
Journal:  Blood Transfus       Date:  2012-03-28       Impact factor: 3.443

Review 2.  The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network.

Authors:  Niels W C J van de Donk; Antonio Palumbo; Hans Erik Johnsen; Monika Engelhardt; Francesca Gay; Henrik Gregersen; Roman Hajek; Martina Kleber; Heinz Ludwig; Gareth Morgan; Pellegrino Musto; Torben Plesner; Orhan Sezer; Evangelos Terpos; Anders Waage; Sonja Zweegman; Hermann Einsele; Pieter Sonneveld; Henk M Lokhorst
Journal:  Haematologica       Date:  2014-03-21       Impact factor: 9.941

3.  The relationship between hypogammaglobulinemia, monoclonal gammopathy of undetermined significance and humoral immunodeficiency: a case series.

Authors:  Robert Marc Zemble; Patricia A Takach; Arnold I Levinson
Journal:  J Clin Immunol       Date:  2011-06-05       Impact factor: 8.317

4.  Utility of testing for monoclonal bands in serum of patients with suspected osteoporosis: retrospective, cross sectional study.

Authors:  Bo Abrahamsen; Ivan Andersen; Susanne S Christensen; Jonna Skov Madsen; Kim Brixen
Journal:  BMJ       Date:  2005-03-14

5.  Curcumin for the prevention of progression in monoclonal gammopathy of undetermined significance: A word of caution.

Authors:  A J M Vermorken; J Zhu; W J M VAN DE Ven; Y Cui; J P Fryns
Journal:  Exp Ther Med       Date:  2010-03-01       Impact factor: 2.447

Review 6.  Smoldering multiple myeloma and monoclonal gammopathy of undetermined significance.

Authors:  Joan Bladé; Laura Rosiñol
Journal:  Curr Treat Options Oncol       Date:  2006-05

7.  Immunoglobulin gene transcripts have distinct VHDJH recombination characteristics in human epithelial cancer cells.

Authors:  Jie Zheng; Jing Huang; Yuntao Mao; Shiqing Liu; Xin Sun; Xiaohui Zhu; Teng Ma; Li Zhang; Jiafu Ji; Youhui Zhang; C Cameron Yin; Xiaoyan Qiu
Journal:  J Biol Chem       Date:  2009-03-16       Impact factor: 5.157

8.  Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden.

Authors:  Ingemar Turesson; Stephanie A Kovalchik; Ruth M Pfeiffer; Sigurdur Y Kristinsson; Lynn R Goldin; Mark T Drayson; Ola Landgren
Journal:  Blood       Date:  2013-11-12       Impact factor: 22.113

9.  A Single-Center Retrospective Study to Investigate the Follow-Up of Patients with Monoclonal Proteinemia by Community Physicians in the UK.

Authors:  Indra Ramasamy
Journal:  J Blood Med       Date:  2020-06-11

Review 10.  Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma.

Authors:  Sarah M Tete; Marc Bijl; Surinder S Sahota; Nicolaas A Bos
Journal:  Front Immunol       Date:  2014-06-03       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.